Suchergebnisse - (Subject:"2494G1JF75")

PubPharm (1.007)

101

Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system

enthalten in: Nanomedicine (London, England) | 2017

von Liptrott, N. | Giardiello, M. | McDonald, T. | +2

102

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach : an observational analysis within the randomised, open-label, EARNEST trial

enthalten in: The lancet. HIV | 2017

von Paton, N. | Kityo, C. | Thompson, J. | +112

CommentIn: Lancet HIV. 2017 Aug;4(8):e323-e324. - PMID 28495563

103

Impairment of the activin A autocrine loop by lopinavir reduces self-renewal of distinct human adipose progenitors

enthalten in: Scientific reports | 2017

von Ravaud, C. | Paré, M. | Azoulay, S. | +2

104

Therapeutic drug monitoring of boosted PIs in HIV-positive patients : undetectable plasma concentrations and risk of virological failure

enthalten in: The Journal of antimicrobial chemotherapy | 2017

von Calcagno, A. | Pagani, N. | Ariaudo, A. | +8

105

Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)

enthalten in: The Journal of antimicrobial chemotherapy | 2017

von Milinkovic, A. | Benn, P. | Arenas-Pinto, A. | +9

106

Cyclosporine A in addition to standard ART during primary HIV-1 infection : pilot randomized clinical trial

enthalten in: The Journal of antimicrobial chemotherapy | 2017

von Nicolás, D. | Ambrosioni, J. | Sued, O. | +15

107

Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir

enthalten in: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria | 2017

von Pelufo-Pellicer, A. | López-Montenegro Soria, M.

108

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir

enthalten in: AIDS (London, England) | 2017

von Jose, S. | Nelson, M. | Phillips, A. | +8

109

Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results

enthalten in: Xenobiotica; the fate of foreign compounds in biological systems | 2017

von Yang, W. | Xiao, Q. | Wang, D. | +2

110

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen : a substudy of the randomised, open-label, non-inferiority SECOND-LINE study

enthalten in: The lancet. HIV | 2017

von Boyd, M. | Amin, J. | Mallon, P. | +14

CommentIn: Lancet HIV. 2017 Jun;4(6):e240. - PMID 28576610